NASDAQ$FATE
Fate Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Fate Therapeutics reported revenue of $44.4 million for Q4 2022, derived from collaborations with Janssen and ONO. The company ended the year with approximately $475 million in cash, cash equivalents, and receivables. They are focusing on advancing innovative programs and reducing expenses to achieve key clinical milestones.
- Initiated multi-dose treatment cohorts in FT576 Phase 1 study for multiple myeloma, with interim data showing objective responses and selective depletion of activated host immune cells from single-dose cohorts.
- Planned mid-2023 IND submission for FT522 NK cell program in B-cell lymphoma, with intent to expand clinical investigation to include severe autoimmune disorders.
- Continued FT819 Phase 1 study of iPSC-derived CAR T-cell therapy, with interim data showing a favorable safety profile and complete responses in large B-cell lymphoma.
- Planned 2023 IND submission for FT825/ONO-8250 CAR T-cell product candidate for solid tumors under Ono collaboration.
Headline financials
Revenue & EPS history
Fate Therapeutics · Revenue · Quarterly
$44.4M
Revenue by segment
Fate Therapeutics · $1.9M total across 1 segment · Q3 2023
- Collaboration Revenue$1.9M-87.3%100.0%
Forward guidance
Fate Therapeutics plans to advance its most innovative programs, submit IND applications for FT522 and FT825/ONO-8250, and wind down collaboration activities with Janssen.
Tailwinds
- Advancing FT576 into multi-dose treatment cohorts for multiple myeloma.
- Planning IND submission for FT522 in mid-2023 for B-cell lymphoma and autoimmune disorders.
- Continuing dose escalation in FT819 Phase 1 study for B-cell malignancies.
- Planning IND submission for FT825/ONO-8250 in 2023 for solid tumors.
- Expecting to receive milestone payments under the Janssen collaboration agreement.
Headwinds
- Termination of Janssen collaboration agreement.
- Discontinuing development of FT516, FT596, FT538, and FT536 NK cell programs.
- Reducing workforce in the first quarter of 2023.
- Expecting to incur charges for severance and other employee termination-related costs.
- Winding down all collaboration activities with Janssen.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+0.8%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
44%
20 / 45 earnings
Positive
+19.0%
Q2 2016
Best reaction
-15.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.9% | -22.8% | -8.5% | |
| Q4 2025 | +6.1% | -7.4% | -20.9% | |
| Q3 2025 | -2.1% | +6.1% | +16.2% | |
| Q1 2025 | -3.7% | +22.0% | +27.0% | |
| Q4 2024 | -1.6% | +2.2% | +20.7% | |
| Q3 2024 | -15.2% | -21.1% | -24.6% | |
| Q2 2024 | -1.8% | +2.1% | +12.3% | |
| Q1 2024 | +10.3% | +14.1% | -0.5% | |
| Q4 2023 | +7.2% | +11.2% | +5.5% | |
| Q3 2023 | -7.8% | -13.9% | -3.0% | |
| Q2 2023 | -4.2% | -13.0% | -30.4% | |
| Q1 2023 | +4.2% | -7.9% | -11.3% | |
| Q4 2022 | +1.3% | +1.7% | -11.8% | |
| Q3 2022 | -1.0% | -2.1% | +4.3% | |
| Q2 2022 | +6.3% | +11.5% | -12.8% | |
| Q1 2022 | -5.5% | -22.3% | -17.8% | |
| Q4 2021 | -1.5% | -7.0% | +14.1% | |
| Q3 2021 | +1.7% | +1.1% | -20.5% | |
| Q2 2021 | +14.8% | +15.0% | -12.3% | |
| Q1 2021 | -4.0% | -5.0% | -8.7% | |
| Q4 2020 | -9.6% | +1.2% | -24.4% | |
| Q3 2020 | -3.1% | +5.6% | +22.0% | |
| Q2 2020 | +2.5% | +10.4% | -4.6% | |
| Q1 2020 | -0.3% | -1.4% | +14.4% | |
| Q4 2019 | -3.3% | +0.9% | -30.8% | |
| Q3 2019 | -12.5% | -4.6% | -11.3% | |
| Q2 2019 | -3.8% | -2.9% | -6.0% | |
| Q1 2019 | -7.8% | -2.6% | -1.1% | |
| Q4 2018 | -3.1% | -0.1% | +12.0% | |
| Q3 2018 | +18.4% | +16.5% | +23.3% | |
| Q2 2018 | +15.6% | +17.6% | +28.6% | |
| Q1 2018 | -14.0% | -10.4% | +8.7% | |
| Q4 2017 | -1.6% | -0.8% | -20.8% | |
| Q3 2017 | -1.0% | +4.0% | -8.0% | |
| Q2 2017 | +6.7% | -3.4% | +44.6% | |
| Q1 2017 | +1.2% | -1.0% | -24.7% | |
| Q4 2016 | +5.5% | -3.4% | -10.4% | |
| Q3 2016 | +10.8% | +50.3% | +53.3% | |
| Q2 2016 | +19.0% | +21.3% | +20.9% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | +15.9% | — | — | |
| Q2 2015 | -5.1% | — | — | |
| Q1 2015 | -0.3% | — | — | |
| Q4 2014 | +3.9% | — | — | |
| Q3 2013 | +1.9% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro